Artisan Partners released its second-quarter 2025 investor letter highlighting the strong but volatile performance of its small-cap funds. The ARTSX fund returned 7.30%, APDSX returned 7.33%, and APHSX returned 7.36%, compared to the Russell 2000 Growth Index’s 11.97% return. Check out the fund’s top 5 holdings for 2025 picks.

Halozyme Therapeutics, Inc. (HALO) was featured in Artisan Small Cap Fund’s investor letter, with a one-month return of 24.41% and a 52-week gain of 15.54%. The stock closed at $71.82 per share on August 22, 2025, with a market capitalization of $8.4 billion. The company develops proprietary enzymes and devices.

In the second quarter 2025 investor letter, Artisan Small Cap Fund mentioned Halozyme Therapeutics, Inc. as a detractor due to uncertainty surrounding new draft guidance from the Centers for Medicare and Medicaid Services on drug pricing. The company reported strong earnings and raised its full-year guidance in May but faced share price impacts.

Halozyme Therapeutics, Inc. (HALO) reported total revenue of $326 million in the second quarter of 2025, a 41% increase over the prior year. While the company shows potential as an investment, 40 hedge fund portfolios held HALO at the end of the second quarter, down from 31 in the previous quarter. Consider AI stocks for greater upside potential and less downside risk.

Read more at Yahoo Finance: Halozyme Therapeutics (HALO) Fell Despite Reporting Strong Earnings and Improved Guidance